May 15, 2023 ImmPACT Bio Granted FDA Fast Track Designation for IMPT-314 in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma Read Article
May 10, 2023 ImmPACT Bio to Present at the 2023 RBC Capital Markets Global Healthcare Conference Read Article
May 8, 2023 ImmPACT Bio Announces Opening of California-Based GMP Facility for Clinical Production of IMPT-314, a CD19/CD20 CAR T Therapy for B-Cell Malignancies and Autoimmune Diseases Read Article
